Culley Brian M 4

What Happened

• Brian M. Culley, President & CEO and a director of Lineage Cell Therapeutics (LCTX), received a grant of derivative securities representing 3,250,000 shares on March 5, 2026. The award shows an acquisition price of $0.00 (no cash paid at grant) and is reported as a derivative grant (code A), not an immediate transfer of common shares.

Key Details

• Transaction date: 2026-03-05; Form 4 filed: 2026-03-06 (appears timely; Form 4 is generally due within 2 business days).
• Grant size and price: 3,250,000 derivative shares at $0.00.
• Vesting: Per footnote — 25% vests on March 5, 2027, then the remaining balance vests in 36 monthly installments thereafter, subject to continued employment.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Nature of transaction: Award/derivative grant (A). This is a compensation grant subject to vesting, not an open-market purchase or sale.

Context

• Because this is a derivative grant subject to vesting, it does not represent immediate share ownership or a cash purchase/sale; the economic interest will depend on vesting and any future exercise terms. Such grants are common for executive compensation and do not, by themselves, indicate a near-term market action.